Prime Medicine annual revenue
2020
2021
2022
2023
2024
2025
Prime Medicine Revenue Growth & History (PRME)
Prime Medicine reported $4.6M in revenue for fiscal 2025, an increase of 55.28% from the previous fiscal year.
View full Prime Medicine company overviewPrime Medicine annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.6M | $1.6M | +55.28% |
| 2024 | 2024-12-31 | $3.0M | $3.0M | — |
| 2023 | 2023-12-31 | $0 | $0 | — |
| 2022 | 2022-12-31 | $0 | $0 | — |
| 2021 | 2021-12-31 | $0 | −$5.2M | −100.00% |
| 2020 | 2020-12-31 | $5.2M | — | — |
Prime Medicine quarterly revenue
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.2M | $39,000 | +3.50% |
| Q1 2026 | 2026-03-31 | $856,000 | −$598,000 | −41.13% |
| Q4 2025 | 2025-12-31 | $838,000 | −$1.3M | −61.61% |
| Q3 2025 | 2025-09-30 | $1.2M | $1.0M | +486.12% |
| Q2 2025 | 2025-06-30 | $1.1M | $1.1M | — |
| Q1 2025 | 2025-03-31 | $1.5M | $863,000 | +146.02% |
| Q4 2024 | 2024-12-31 | $2.2M | $2.2M | — |
| Q3 2024 | 2024-09-30 | $209,000 | $209,000 | — |
| Q2 2024 | 2024-06-30 | $0 | $0 | — |
| Q1 2024 | 2024-03-31 | $591,000 | $591,000 | — |
| Q4 2023 | 2023-12-31 | $0 | — | — |
| Q3 2023 | 2023-09-30 | $0 | — | — |
| Q2 2023 | 2023-06-30 | $0 | — | — |
| Q1 2023 | 2023-03-31 | $0 | — | — |
Prime Medicine revenue growth trends
Over the last five reported fiscal years, revenue declined from $5.2M to $4.6M, a compound annual decline of 2.32%. Prime Medicine's latest reported quarter, Q2 2026, generated $1.2M in revenue, an increase of 3.50% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Prime Medicine source filings ↗Community posts
Prime Medicine receives FDA clearance to test PM647 in humans
Prime Medicine ($PRME) received FDA clearance for its investigational new drug application for PM647, a prime-editing candidate for alpha-1 antitrypsin deficiency. The decision allows a first-in-human Phase 1/2 study of a single intravenous ...
